GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Degree of Financial Leverage

Mustang Bio (Mustang Bio) Degree of Financial Leverage : 1.24 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Mustang Bio's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 1.24. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Mustang Bio's Degree of Financial Leverage or its related term are showing as below:

MBIO's Degree of Financial Leverage is ranked worse than
70.38% of 1499 companies
in the Biotechnology industry
Industry Median: 0.96 vs MBIO: 1.24

Mustang Bio Degree of Financial Leverage Historical Data

The historical data trend for Mustang Bio's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio Degree of Financial Leverage Chart

Mustang Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only 0.29 -0.45 -1.85 -0.96 1.26

Mustang Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.36 1.66 1.19 1.26 1.24

Competitive Comparison of Mustang Bio's Degree of Financial Leverage

For the Biotechnology subindustry, Mustang Bio's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Degree of Financial Leverage falls into.



Mustang Bio Degree of Financial Leverage Calculation

Mustang Bio's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -4.4 (Mar. 2024) / -9.46 (Mar. 2023) - 1 )/( -39.961 (Mar. 2024) / -70.118 (Mar. 2023) - 1 )
=-0.5349/-0.4301
=1.24***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Mustang Bio  (NAS:MBIO) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Mustang Bio Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mustang Bio (Mustang Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
377 Plantation Street, Worcester, MA, USA, 01605
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Executives
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman director, officer: President and CEO 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach officer: SVP, Fin. & Corp. Controller 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill director 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky director
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Mustang Bio (Mustang Bio) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023